Healthcare Industry News: InterMune
News Release - January 4, 2008
Trellis Bioscience Appoints John Wulf as EVP, Business Operations and Chief Business OfficerSOUTH SAN FRANCISCO, Calif.--(HSMN NewsFeed)--Trellis Bioscience, a privately held biotechnology company, today announced the appointment of John J. Wulf as Executive Vice President, Business Operations and Chief Business Officer. Mr. Wulf, a senior corporate development executive with over 20 years experience within the biotechnology industry, joins Trellis Bioscience from Y’s Therapeutics, where he was President, Chief Operating Officer and Chief Business Officer.
“John Wulf has a proven track record of success in both general and operations management, as well as business development in large biotechnology, specialty pharma and R&D stage companies,” said Brian Cunningham, President and Chief Executive Officer of Trellis Bioscience. “His broad based experience will serve our company well as we seek to capitalize on the partnering potential of our CellSpot antibody screening technology, as well as move our initial human antibody therapeutic candidates toward clinical testing. We are pleased to welcome John to the Trellis Bioscience team.”
Prior to joining Y’s Therapeutics, Mr. Wulf was Senior Vice President, Corporate Development at InterMune, Inc. from 2000 to 2003, where he was responsible for corporate development strategy and business development activities. From 1998 to 2000, he was Vice President, Business Development at Axys Pharmaceuticals (prior to its acquisition by Celera). Before that, he was employed at Genentech from 1981 to 1998 in a series of increasingly responsible positions, ultimately serving as Director, Business and Corporate Development. He holds an MS from Oregon State University and an MBA degree from San Francisco State University.
About Trellis Bioscience
Trellis Bioscience, Inc. discovers and develops novel human antibody therapeutics as treatments for infectious disease and oncology indications. The company leverages its proprietary platform technology, CellSpot, to find rare human antibodies with superior selectivity, affinity and other characteristics. The company is progressing its early stage pipeline into preclinical studies. For additional information on the company, please visit our website at http://www.trellisbio.com.
Source: Trellis Bioscience
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.